AnaptysBio is a US-based pharmaceutical company with an ESG risk rating score of 25.4, indicating a medium risk assessment. Specializing in developing antibody products for inflammation and immuno-oncology, AnaptysBio focuses on immune cell modulating antibodies for autoimmune and inflammatory diseases. With clinical-stage development of checkpoint agonists like rosnilimab and ANB032, the company aims to address unmet medical needs.